Boryung seeks additional indication of Astrix

Published: 2008-03-19 06:58:00

Updated: 2008-03-19 06:58:00

Boryung Pharm has tried to expand the treatment scope of Astrix (aspirin 100 mg) to cardiovascular disease (i.e., hypertension), citing that the benefit of aspirin for patients with known CVD is well established.

Nevertheless, the Korea Food and Drug Administration has yet to respond to Boryun...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK